-5%
Bexitrol F contains two active components: Salmeterol Xinafoate and Fluticasone Propionate, each serving a unique purpose in managing asthma and related airway conditions:
Salmeterol Xinafoate:
- This is a long-acting beta-2 adrenoceptor agonist (LABA) that provides extended (12-hour) bronchodilation.
- Its mechanism involves binding to the exo-site of the beta-2 receptor, allowing prolonged action.
Fluticasone Propionate:
- A corticosteroid with potent anti-inflammatory properties.
- When inhaled, it exerts a localized action in the lungs, enhancing lung function, reducing inflammation, and preventing exacerbations without significant systemic effects at standard doses.
This combination ensures both symptom relief (via Salmeterol) and long-term management of airway inflammation (via Fluticasone), offering a convenient therapeutic option for patients requiring both treatments concurrently.
